GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that the Arexvy vaccine (MAL24086007ARZ) has been approved in Malaysia for respiratory syncytial virus (RSV). RSV is a common respiratory ...

The first RSV vaccines were approved in the US in May last year. GSK’s Arexvy vaccine generated more than $1bn in sales in ...

In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.

Results looking at the first season of RSV use shows that it is 75% effective at preventing RSV-associated hospitalizations ...

Data from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving ...

GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

Trial met primary endpoint, non-inferior immune response for both vaccines when co-administered compared with separate ...

GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine Arexvy and shingles vaccine Shingrix — in ...

Respiratory syncytial virus, or RSV, season is just a few months away, but new vaccine options have already arrived for ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.